<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004015</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-11961</org_study_id>
    <secondary_id>EORTC-11961</secondary_id>
    <nct_id>NCT00004015</nct_id>
  </id_info>
  <brief_title>Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery</brief_title>
  <official_title>Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming
      normal tissue.

      PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron
      capture therapy following surgery in treating patients with glioblastoma multiforme removed
      during surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine systemic and local toxicity of borocaptate sodium with boron neutron capture
           therapy (BNCT) following craniotomy with gross total resection in patients with
           glioblastoma multiforme.

        -  Determine the qualitative and quantitative dose-limiting toxicity and maximum tolerated
           dose of this regimen in these patients.

        -  Determine the maximum tolerated radiation dose of BNCT in cranial localization to
           healthy tissues in these patients under defined conditions.

      OUTLINE: This is a dose escalation, multicenter study.

      Within 6 weeks of surgery, patients receive borocaptate sodium followed 12-18 hours later by
      neutron irradiation. Treatment repeats daily for 4 days.

      Cohorts of 3-9 patients receive escalating doses of neutron irradiation. The maximum
      tolerated dose is defined as the dose preceding that at which 3 or more patients experience
      dose limiting toxicity.

      Patients are followed weekly for 4 weeks, monthly for 2 months, every 6 weeks for 15 months
      and then every 3 months thereafter.

      PROJECTED ACCRUAL: Approximately 30-36 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity as measured by NCIC-Common Toxicity Criteria up to 30 days after the first BSH administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity as measured by RTOC and EORTC late radiation morbidity scale from 90 days after completion of irradiation treatment until death</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank until death</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium borocaptate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven glioblastoma multiforme for which conventional radiotherapy
             would be of little or no benefit

          -  Gross total resection of tumor confirmed by postoperative MRI performed within 48
             hours of surgery

          -  Evaluable preoperative and postoperative MRI films with and without contrast must be
             available

          -  No prior brain malignancy

          -  No prior craniotomy except for glioblastoma

        PATIENT CHARACTERISTICS:

        Age:

          -  50 and over

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin, SGOT, SGPT, and alkaline phosphatase no greater than 2.5 times normal
             unless caused by reversible reaction to antiseizure medication

        Renal:

          -  Blood urea nitrogen and creatinine no greater than 2.5 times upper limit of normal

        Cardiovascular:

          -  No severe heart disease (e.g., congestive heart failure, angina pectoris)

        Pulmonary:

          -  No severe dyspnea at time of diagnosis

          -  No severe obstructive or restrictive lung disease

        Other:

          -  No other concurrent malignant tumor

          -  No severe gastrointestinal disease or active peptic ulcer disease

          -  No uncontrolled endocrine disease

          -  No serious mental disease, organic brain disease (e.g., preexisting epilepsy or
             serious aphasia), or legally incapacitated patients

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy for glioblastoma multiforme

          -  No concurrent biologic therapy

        Chemotherapy:

          -  No prior chemotherapy for glioblastoma multiforme

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  No prior endocrine therapy for glioblastoma multiforme except corticosteroids

          -  No concurrent endocrine therapy

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy for glioblastoma multiforme

          -  No prior radiotherapy to head and neck

          -  No other concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  Prior stereotactic biopsy allowed for glioblastoma multiforme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Sauerwein, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EC Joint Research Centre - Institute for Energy</name>
      <address>
        <city>Petten</city>
        <zip>NL-1755 ZG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Wittig A, Moss RL, Stecher-Rasmussen F, Appelman K, Rassow J, Roca A, Sauerwein W. Neutron activation of patients following boron neutron capture therapy of brain tumors at the high flux reactor (HFR) Petten (EORTC Trials 11961 and 11011). Strahlenther Onkol. 2005 Dec;181(12):774-82.</citation>
    <PMID>16362787</PMID>
  </reference>
  <reference>
    <citation>Verbakel WF, Hideghety K, Morrissey J, Sauerwein W, Stecher-Rasmussen F. Towards in vivo monitoring of neutron distributions for quality control of BNCT. Phys Med Biol. 2002 Apr 7;47(7):1059-72.</citation>
    <PMID>11996055</PMID>
  </reference>
  <reference>
    <citation>Hüsing J, Sauerwein W, Hideghéty K, Jöckel KH. A scheme for a dose-escalation study when the event is lagged. Stat Med. 2001 Nov 30;20(22):3323-34.</citation>
    <PMID>11746321</PMID>
  </reference>
  <reference>
    <citation>Rassow J, Stecher-Rasmussen F, Voorbraak W, Moss R, Vroegindeweij C, Hideghéty K, Sauerwein W. Comparison of quality assurance for performance and safety characteristics of the facility for Boron Neutron Capture therapy in Petten/NL with medical electron accelerators. Radiother Oncol. 2001 Apr;59(1):99-108. Review.</citation>
    <PMID>11295213</PMID>
  </reference>
  <reference>
    <citation>Sauerwein W, Moss R, Rassow J, Stecher-Rasmussen F, Hideghéty K, Wolbers JG, Sack H. Organisation and management of the first clinical trial of BNCT in Europe (EORTC protocol 11961).EORTC BNCT study group. Strahlenther Onkol. 1999 Jun;175 Suppl 2:108-11.</citation>
    <PMID>10394415</PMID>
  </reference>
  <reference>
    <citation>Gabel D, Philipp KH, Wheeler FJ, Huiskamp R. The compound factor of the 10B(n,alpha)7Li reaction from borocaptate sodium and the relative biological effectiveness of recoil protons for induction of brain damage in boron neutron capture therapy. Radiat Res. 1998 Apr;149(4):378-86.</citation>
    <PMID>9525503</PMID>
  </reference>
  <reference>
    <citation>Pignol JP, Oudart H, Chauvel P, Sauerwein W, Gabel D, Prevot G. Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy. Br J Radiol. 1998 Mar;71(843):320-3.</citation>
    <PMID>9616243</PMID>
  </reference>
  <results_reference>
    <citation>Verbakel WF, Sauerwein W, Hideghety K, Stecher-Rasmussen F. Boron concentrations in brain during boron neutron capture therapy: in vivo measurements from the phase I trial EORTC 11961 using a gamma-ray telescope. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):743-56.</citation>
    <PMID>12573762</PMID>
  </results_reference>
  <results_reference>
    <citation>Hideghéty K, Sauerwein W, Haselsberger K, Grochulla F, Fankhauser H, Moss R, Huiskamp R, Gabel D, de Vries M. Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961). Strahlenther Onkol. 1999 Jun;175 Suppl 2:111-4.</citation>
    <PMID>10394416</PMID>
  </results_reference>
  <results_reference>
    <citation>Gabel D, Touw D, Stecher-Rasmussen F, et al.: Quality control of Na2B12H11SH, a drug boron neutron capture therapy in EORTC trial 11961. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.</citation>
  </results_reference>
  <results_reference>
    <citation>Hideghéty K, Sauerwein W, Wittig A, Götz C, Paquis P, Grochulla F, Haselsberger K, Wolbers J, Moss R, Huiskamp R, Fankhauser H, de Vries M, Gabel D. Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J Neurooncol. 2003 Mar-Apr;62(1-2):145-56.</citation>
    <PMID>12749710</PMID>
  </results_reference>
  <results_reference>
    <citation>Hideghety W, Sauerwein W, DeVries M, et al.: Post-operative treatment of glioblastoma with boron neutron capture therapy at the European High Flux Reactor Petten (EORTC protocol 11961). [Abstract] Ann Oncol 9(suppl 2): 129, 1998.</citation>
  </results_reference>
  <results_reference>
    <citation>Sauerwein W, Hideghety K, De Vries M, et al.: Boron neutron capture therapy (BNCT) for the treatment of glioblastoma (EORTC protocol 11961). [Abstract] Radiother Oncol 48(suppl 1): s157, 1998.</citation>
  </results_reference>
  <results_reference>
    <citation>Sauerwein W, Hideghety K, De Vries M, et al.: Conducting phase I clinical trial in binary treatment modality: methodical questions for the evaluation of boron neutron capture therapy. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.</citation>
  </results_reference>
  <results_reference>
    <citation>Vos MJ, Turowski B, Zanella FE, Paquis P, Siefert A, Hideghéty K, Haselsberger K, Grochulla F, Postma TJ, Wittig A, Heimans JJ, Slotman BJ, Vandertop WP, Sauerwein W. Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):392-9.</citation>
    <PMID>15667958</PMID>
  </results_reference>
  <results_reference>
    <citation>Haselsberger K, Pendl G, Sauerwein W, et al.: BNCT for glioblastoma in Europe: design of the EORTC protocol 11961 and clinical course of the first patient. [Abstract] J Neurooncol 39 (2): A-P155, 147, 1998.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

